- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01946230
The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma (p62/SQSTM1)
April 25, 2014 updated by: National Taiwan University Hospital
The mortality rate of oral cancer in Taiwan is still high with no decrease.
One of the reasons result in these situations is the patent visits hospital for treatment in late stage of oral cancer.
Recently, the government makes effort in oral cancer screening to find oral potentially malignant disorders (OPMD) early.
However, there is no conscience in treatment strategies of OPMD up to now.
In this study, we will set a OPMD data bank, and use the cases to find out the potential biomarker, which is able to predict the oral cancer malignant transformation.
Sixty OPMD with oral cancer transformation will be recruited, and 60 OPMD with no oral cancer malignant transformation will also be enrolled as the disease control group.
Besides, 20 normal cases and 60 oral cancer cases resulting from previous OPMD will be collected.
All those groups will detect the expression of p62/SQSTM1 to investigate the possibility that p62/SQSTM1 as a biomarker to predict the malignant transformation of OPMM, and a guideline to treat or not to treat OPMD.
Study Overview
Status
Unknown
Study Type
Observational
Enrollment (Anticipated)
2000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 86 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Doctor of Dental Surgery
Description
Inclusion Criteria:
Study group was oral precancerous lesions in patients with malignant transformation; control group was generally no precancerous disease and orthodontic surgery volunteer
Exclusion Criteria:
Oral mucosa of subjects is too thin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
Time Frame: two year
|
two year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Chen Hsin Ming, PHD, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (Anticipated)
August 1, 2014
Study Registration Dates
First Submitted
September 16, 2013
First Submitted That Met QC Criteria
September 16, 2013
First Posted (Estimate)
September 19, 2013
Study Record Updates
Last Update Posted (Estimate)
April 28, 2014
Last Update Submitted That Met QC Criteria
April 25, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- Neoplasms, Squamous Cell
- Disease
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Mouth Neoplasms
Other Study ID Numbers
- 201306005RINC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Cancer
-
Anil ChaturvediNational Taiwan University HospitalRecruitingOral Cancer | Oral Cancer Screening | Oral PrecancerTaiwan
-
Royal Surrey County Hospital NHS Foundation TrustCompleted
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustNot yet recruitingOral Cancer | Dysplasia | Mouth Cancer | Oral Lesions | Oral Pre-cancerUnited Kingdom
-
Combined Military Hospital, PakistanNational University of Medical Sciences, PakistanCompletedOral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity CancerPakistan
-
University of WashingtonBlaze Bioscience Inc.TerminatedStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
Centre Francois BaclesseTerminatedCancer | Cognitive Function | Compliance | Oral TherapiesFrance
-
University of Michigan Rogel Cancer CenterRecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Oral LeukoplakiaUnited States
-
Pai PangActive, not recruitingOral Cancer Patients After Selective Neck DissectionChina
-
Helsinki University Central HospitalKarolinska Institutet; University of HelsinkiCompletedPeriodontal Diseases | Biomarker in Early Diagnosis | Oropharyngeal Cancers | Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity CancerFinland